GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CuraScientific Corp (OTCPK:CSTF) » Definitions » Capex-to-Revenue

CuraScientific (CuraScientific) Capex-to-Revenue : 0.00 (As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is CuraScientific Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

CuraScientific's Capital Expenditure for the three months ended in Sep. 2023 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2023 was $0.23 Mil.

Hence, CuraScientific's Capex-to-Revenue for the three months ended in Sep. 2023 was 0.00.


CuraScientific Capex-to-Revenue Historical Data

The historical data trend for CuraScientific's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CuraScientific Capex-to-Revenue Chart

CuraScientific Annual Data
Trend Dec20 Dec21 Dec22
Capex-to-Revenue
- 0.07 0.44

CuraScientific Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CuraScientific's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, CuraScientific's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CuraScientific's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CuraScientific's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where CuraScientific's Capex-to-Revenue falls into.



CuraScientific Capex-to-Revenue Calculation

CuraScientific's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.015) / 0.034
=0.44

CuraScientific's Capex-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.23
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CuraScientific  (OTCPK:CSTF) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


CuraScientific Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of CuraScientific's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


CuraScientific (CuraScientific) Business Description

Traded in Other Exchanges
N/A
Address
51544 Cesar Chavez Street, Suite No. 1J, Coachella, CA, USA, 92236
CuraScientific Corp manufactures commercial chemicals with a variety of commercial sterilization applications for agriculture, warehousing, hospitality, and medical facilities. The company's product, DiOx+, is a disinfectant sterilizer that kills harmful pathogens without exposing people or the environment to dangerous toxins.
Executives
Paul Quentin Goyette director 2205 LOCH WAY, EL DORADO HILLS CA 95762
William Joseph Reed director, officer: Chief Executive Officer 333 N UNIVERSITY AVE., #33, REDLANDS CA 92374
Johann Loewen director C/O METHES ENERGIES INTERNATIONAL LTD, 3651 LINDELL ROAD, SUITE D-272, LAS VEGAS NV 89103
Edouard Maurice Beaudette director 13480 N BLOOMFIELD ROAD, NEVADA CITY CA 95959
Justin Michael Gonzalez director, officer: Chief Executive Officer 15723 LAKE VERA PURDON RD., NEVADA CITY CA 95959
Eric Jason Watson director, officer: Chief Operating Officer 19553 BOWERS DRIVE, TOPANGA CA 90290

CuraScientific (CuraScientific) Headlines

From GuruFocus

Introducing Leaf of Faith

By Marketwired Marketwired 03-26-2019